{"entity":{"id":"nct06351631","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)","aka":[],"tldr":"A phase 3 trial testing Bomedemstat in myeloproliferative neoplasms, now recruiting.","summary":"A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) is a phase 3 interventional study registered as NCT06351631, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study. Planned enrolment is 400 participants (estimated). The study started in 2024-05-23 and primary completion is expected in 2034-12-04. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06351631","url":"https://clinicaltrials.gov/study/NCT06351631"}],"tags":["ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":["lsd1-inhibitors"],"targets":[],"drugs":["bomedemstat"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06351631","phase":"3","setting":"A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study","sponsor":"Merck Sharp & Dohme","participation":[{"nct":"NCT06351631","source":"https://clinicaltrials.gov/study/NCT06351631","fetchedAt":"2026-10-07T16:54:34.595Z","studySha256":"b65c5b53b2c8fa3731194d0c994b706e832292910b6ceff9fc17cce2c4b47aff","overallStatus":"RECRUITING","lastUpdatePosted":"2026-04-02","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":400,"enrolmentType":"ESTIMATED","siteCount":21,"recruitingSiteCount":18,"countries":["Australia","Hong Kong","Italy","New Zealand","United Kingdom","United States"]}],"started":"2024-05-23","startedType":"actual","enrolled":400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06351631/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"technology":[{"id":"lsd1-inhibitors","kind":"technology","name":"LSD1 inhibitors","route":"/technologies/lsd1-inhibitors/"}],"drug":[{"id":"bomedemstat","kind":"drug","name":"Bomedemstat","route":"/drugs/bomedemstat/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}